BCBS Tennessee Thyroid Testing Coverage

Coverage Criteria and Clinical Indications

Medically Necessary / Covered Indications

Covered when specified clinical indications or monitoring needs are met

Covered testing indications: Any of the following indications meet coverage: (a) signs/symptoms consistent with hypothyroidism: TSH to confirm or rule out primary hypothyroidism; fT4 as follow-up to abnormal TSH; TSH and fT4 for suspected secondary (central) hypothyroidism; monitoring with TSH and fT4 every 6 weeks after levothyroxine dose changes and annually when stable; (b) signs/symptoms consistent with hyperthyroidism: TSH to confirm or rule out overt hyperthyroidism; fT4 follow-up to abnormal TSH; TT3 or fT3 to confirm hyperthyroidism; fT4 to distinguish overt versus subclinical hyperthyroidism; monitoring after treatment (repeat TSH and fT4 every 8 weeks, then annual monitoring); (c) asymptomatic individuals at high risk (personal or family history of thyroid dysfunction, type 1 diabetes or other autoimmune disease, medications that interfere with thyroid function) — testing annually and when medications change or symptoms develop; (d) individuals capable of becoming pregnant undergoing infertility evaluation or with >=2 pregnancy losses; (e) individuals with disease or neoplasm of the thyroid or other endocrine glands; (f) chronic or acute urticaria; (g) individuals undergoing immune reconstitution therapy (eg, alemtuzumab, HAART, post-BMT/HSCT) — TSH testing and ongoing monitoring; (h) suspected central hypothyroidism; (i) primary mitochondrial disease — annual TSH and fT4; (j) pediatric short stature or failure-to-thrive evaluation; (k) pregnant/postpartum symptomatic individuals — TSH and fT4 every 4 weeks; (l) pregnant/postpartum with diagnosed hyperthyroidism — TT4, Tg-Ab, TRAb, and TPOAb; (m) thyroid cancer surveillance — serum thyroglobulin and/or Tg-Ab for detection of recurrence, post-surgical evaluation, surveillance and maintenance; (n) thyroid antibody testing in diagnosed hypo- or hyperthyroidism — once every 3 years.

Not Medically Necessary / Exclusions

Not covered in the following situations

Not covered tests/uses: The following tests/uses DO NOT MEET COVERAGE: testing TRH or TBG to evaluate the cause of hyperthyroidism or hypothyroidism; routine use of reverse T3, T3 uptake, and total T4 (TT4) in unspecified situations; measurement of TT3 and/or fT3 for assessment of hypothyroidism; measurement of total or fT3 to assess levothyroxine dose in hypothyroid patients; and screening/testing of asymptomatic nonpregnant individuals during a general exam without abnormal findings.

Guideline-based coverage criteria (informational)

Guideline-based testing and monitoring scenarios referenced:

Screening in asymptomatic adults: USPSTF: current evidence is insufficient to assess benefits/harms of screening asymptomatic, non-pregnant adults; USPSTF also recommends against screening for thyroid cancer in asymptomatic adults.

References USPSTF

Pregnancy screening: ACOG: universal screening in pregnancy is not recommended; when testing is indicated, measure TSH as the first-line test.

ACOG guidance

Monitoring treated pregnant women: Monitor TSH every 4–6 weeks while adjusting levothyroxine with a target TSH between the lower reference limit and 2.5 mU/L; pregnant women with hypothyroidism or at risk should have TSH every 4 weeks until mid-gestation and at least once near 30 weeks.TSH <= 2.5 mU/L (treatment target in pregnancy)

ACOG/ATA guidance

Medically necessary testing and monitoring

Covered and recommended testing when clinically indicated or in higher-risk groups, particularly for pregnancy and symptomatic patients.

Initial screening: Serum TSH is the recommended initial screening test for suspected thyroid dysfunction; measure fT4 to confirm or clarify diagnosis when TSH is abnormal.

Supported by ASCP, Endocrine Society, ATA

Pregnancy: high-risk screening and monitoring: Obtain serum TSH early in pregnancy for women with risk factors (history of thyroid disease, age >30, symptoms/goiter, TPOAb positivity, type 1 diabetes, recurrent miscarriage, prior radiation/surgery, family history, morbid obesity, certain medications, infertility, iodine insufficiency); apply trimester-specific TSH ranges; monitor TSH every 4 weeks until mid-pregnancy and at least once near 30 weeks for women with hypothyroidism or at risk; measure TRAb at recommended gestational windows for women with history of Graves disease or prior ablation.

ATA/ETA statements

Postpartum and postpartum thyroiditis (PPT): Women with postpartum depression should have TSH, fT4, and TPOAb testing; after the thyrotoxic phase of PPT measure TSH in approximately 4–8 weeks to detect hypothyroid phase; women with prior PPT should have annual TSH testing.

Testing indications and monitoring schedules

Covered when testing follows guideline-recommended indications or monitoring schedules.

Indications for testing: Testing is indicated for clinical suspicion of thyroid disease, new-onset atrial fibrillation, type 1 diabetes or other autoimmune disease, depression/unexplained anxiety, abnormal growth or behavior in children/young people, pregnancy with history of autoimmune thyroid disease, subfertility evaluation, and other guideline-specified risk states.

NICE, ETA, SMFM references

Monitoring in pregnancy with autoimmune disease: Measure maternal fT4 and TSH every 2 weeks after initiation of therapy and every 4 weeks after achieving target; obtain TSH-R-Ab at presentation in pregnancy and if maternal TSH-R-Ab remains >3× the normal cutoff, monitor the fetus for thyroid dysfunction throughout pregnancy.TSH-R-Ab >3x cutoff

ETA guidance

Central hypothyroidism diagnosis: Confirm central hypothyroidism (CeH) by combined low FT4 and inappropriately low/normal TSH on at least two separate determinations after excluding listed conditions; isolated low FT3 is not diagnostic of CeH.

The policy identifies several specific tests and uses that DO NOT MEET COVERAGE CRITERIA. Specifically, measurement of thyrotropin-releasing hormone (TRH) or thyroxine-binding globulin (TBG) to evaluate the cause of hyperthyroidism or hypothyroidism is not covered. Likewise, testing of reverse T3, T3 uptake, and total T4 (TT4) in unspecified situations is not covered. Measurement of total T3 (TT3) and/or free T3 (fT3) to assess hypothyroidism, and use of total or free T3 to guide levothyroxine dosing in hypothyroid patients, DO NOT MEET COVERAGE. Finally, thyroid testing for asymptomatic nonpregnant individuals during a general exam without abnormal findings DOES NOT MEET COVERAGE CRITERIA.

The USPSTF conclusions cited in the policy state that current evidence is insufficient to assess the balance of benefits and harms of screening for thyroid dysfunction in asymptomatic, nonpregnant adults. In addition, the USPSTF specifically recommends against screening for thyroid cancer in asymptomatic adults; routine population screening for thyroid cancer is therefore not supported by this guidance.

Multiple society guidelines referenced in the policy advise against routine measurement of thyroid autoantibodies in euthyroid patients. ACOG and ATA/AACE note that routine TPOAb testing in women who are euthyroid is not recommended because antibody detection alone has not been shown to improve pregnancy outcomes. The policy aligns with these recommendations and does not support universal TSH screening of asymptomatic adults or universal fT4 screening in pregnancy; antibody testing should be reserved for guideline-directed indications such as subclinical hypothyroidism, recurrent miscarriage, or specific pregnancy risk scenarios.

The policy reiterates that routine measurement of thyroid autoantibodies during surveillance of euthyroid patients is not recommended and may be considered not medically necessary. Society guidance from SMFM also advises against screening asymptomatic pregnant women for subclinical hypothyroidism; thyroid testing in pregnancy should be targeted to women at increased risk rather than applied universally to all pregnant patients.

The Society for Maternal-Fetal Medicine (SMFM) recommendation is cited in the policy references: SMFM advises that clinicians should not screen asymptomatic pregnant women for subclinical hypothyroidism. This citation is provided as part of the guideline references supporting targeted, risk-based testing in pregnancy rather than universal screening.

The policy explains that testing such as reverse T3, T3 uptake, and TT4 is not covered in most unspecified situations, and that measurement of TT3/fT3 to assess hypothyroidism or to titrate levothyroxine dosing is not supported. The document cites analytic and clinical limitations of current T3 assays and evidence that reverse T3 cannot reliably distinguish hypothyroidism from euthyroidism, underscoring why routine use of these tests for general assessment is not accepted as medically necessary.

For patients with hypothyroidism who are being treated with levothyroxine, routine measurement of T3 (including fT3) is not supported as part of monitoring; evidence shows limited clinical utility of T3 testing in this setting. Measurement of reverse T3 is also of limited diagnostic value and is not recommended for routine clinical decision-making.

The policy emphasizes that serum TSH should be the preferred initial test for evaluation of suspected thyroid dysfunction and that routine TSH screening at annual well visits for asymptomatic adults is not supported. The ASCP recommends against ordering multiple tests for an initial evaluation; start with TSH and confirm diagnoses with free T4 as indicated. Ordering multiple simultaneous tests in the absence of clinical indication is discouraged and may not meet coverage.

The policy restates that routine measurement of thyroid autoantibodies during surveillance of euthyroid patients is not recommended and may be considered not medically necessary. Antibody testing is covered when indicated by guideline-directed situations (for example, evaluation of subclinical hypothyroidism, recurrent miscarriage, or specified pregnancy scenarios), but not for routine periodic surveillance of patients with normal thyroid function tests.

Provider Actions, Documentation, and Operational Notes

Note

Testing sequence

Testing sequence: Begin evaluation with serum TSH as the preferred first‑line test. If TSH is abnormal, obtain free T4 (fT4) to clarify hypothyroidism; if TSH is low, consider fT4 and free or total T3 to assess hyperthyroidism. Measure both TSH and fT4 when secondary (pituitary/hypothalamic) dysfunction is suspected. Do not routinely order multiple thyroid hormone tests at initial evaluation — start with TSH and cascade per results.

Start with TSH; cascade to fT4 or fT3/TT3 based on TSH result
Do not order TSH+fT4+fT3 routinely for initial screening

Documentation Required

Serial/targeted testing in pregnancy and post‑IRT

Serial/targeted testing in pregnancy and post‑immune reconstitution therapy (IRT): For pregnant women with hypothyroidism or at risk, monitor TSH every 4 weeks until mid‑gestation and at least once near 30 weeks; monitor fT4 as indicated for hyperthyroidism and adjust therapy to pregnancy‑specific targets. For women with prior Graves disease or prior ablation, obtain TRAb at presentation and repeat at 18–22 weeks and again in late pregnancy (30–34 weeks) if elevated or if on antithyroid drugs. In patients after alemtuzumab or other IRT, follow ETA guidance for frequent monitoring (eg, every 3 months for 4 years after alemtuzumab) and as specified by transplantation/HAART protocols.

Pregnancy: TSH every 4 weeks while adjusting levothyroxine; fT4 monitoring for hyperthyroidism every 2–4 weeks per guideline
TRAb: initial in early pregnancy if prior Graves; repeat at 18–22 weeks and 30–34 weeks when indicated
Post‑IRT (eg, alemtuzumab): continued 3‑monthly testing for recommended duration (ETA guidance)

Documentation Required

Required documentation to support testing

Required documentation to support testing: Document clinical signs/symptoms consistent with hypo‑ or hyperthyroidism, pregnancy/postpartum status (including trimester), history of thyroid disease (eg, Graves, prior ablation or surgery), use of medications affecting thyroid function (eg, amiodarone, lithium, antithyroid drugs), IRT/transplantation history, and the specific clinical question being addressed. For monitoring, document current therapy, recent dose changes, and prior laboratory results showing need for repeat testing.

Indication and clinical context (symptoms, risk factors, pregnancy trimester)
Therapy status and recent dose changes for levothyroxine or antithyroid drugs
Prior test results when ordering follow‑up/monitoring tests

Documentation Required

Indication documentation

Indication documentation: When ordering TSH, fT4, fT3, or antibody testing, document the medical indication (eg, suspected hypo/hyperthyroidism, infertility evaluation, recurrent pregnancy loss, monitoring after therapy, symptoms suggestive of thyroid dysfunction, IRT/transplant monitoring). For antibody testing in pregnancy, document history of Graves disease or prior ablation when ordering TRAb.

Specify clinical indication on the order and in the medical record
For TRAb testing, note prior Graves disease, ablation, or current antithyroid drug therapy

Denial Risk

Denial triggers

Denial triggers / Not covered testing: Requests for TRH stimulation testing, thyroxine‑binding globulin (TBG), reverse T3, T3 uptake, routine total T4/TT4, total or free T3 to assess levothyroxine dose, and reverse T3 or other non‑recommended assays in unspecified situations are excluded and may be denied unless a clear, guideline‑supported clinical rationale is documented. Routine screening of asymptomatic, nonpregnant individuals without risk factors is not covered.

TRH, TBG, reverse T3, T3 uptake — does NOT meet coverage criteria except with strong documented justification
TT3/FT3 measurement not indicated to adjust levothyroxine dose — not covered
Screening in asymptomatic nonpregnant individuals without risk factors — not covered

Note

Monitoring expectation

Monitoring expectation: For patients treated for hypothyroidism, monitor TSH (and fT4 when indicated) every 6 weeks after a dosage change and annually when stable. For hyperthyroid patients on therapy, repeat TSH and fT4 every ~6–8 weeks while titrating, then at recommended intervals thereafter. Follow pregnancy‑specific monitoring frequency (eg, every 4 weeks while adjusting therapy) and transplant/IRT monitoring schedules per specialty guidance.

Hypothyroidism: TSH every 6 weeks after dose change; annually if stable
Hyperthyroidism: TSH and fT4 every 6–8 weeks while adjusting therapy
Pregnancy: TSH monitoring every 4 weeks while adjusting levothyroxine; TRAb and fetal monitoring timing as indicated

Denial Risk

Risk of non‑supported screening/testing approach

Risk of non‑supported screening/testing approach: Ordering multiple thyroid tests at initial evaluation instead of starting with TSH increases costs and may lead to inappropriate testing. Overuse of fT3/fT4 or antibody panels in euthyroid, asymptomatic patients is discouraged and may result in denial. Underuse of regular TSH monitoring in patients on thyroid hormone replacement is also a quality concern.

Avoid ordering broad panels (TSH+fT4+fT3) for routine screening
Document justification when deviating from TSH‑first approach
Ensure regular TSH monitoring for patients on therapy to avoid care gaps

Billing Rule

Procedure code reference

Procedure code reference: The following CPT/HCPCS codes are provided for reference; verify payer‑specific billing and prior authorization requirements before submission. This list is not exhaustive.

84443 — Thyroid stimulating hormone (TSH)
84439 — Thyroxine; free (fT4)
84480 — Triiodothyronine T3; total (TT3)
84481 — Triiodothyronine T3; free (fT3)
84436 — Thyroxine; total (TT4)
84445 — Thyroid stimulating immune globulins (TSI)
86376 — Microsomal (thyroid) antibodies
86800 — Thyroglobulin antibody
84442 — Thyroxine binding globulin (TBG) — listed (not covered generally)

Note

References include UpToDate and guideline citations

References and justification resources: Clinical guideline and review sources (ACOG, ATA/AACE, Endocrine Society, NICE, ASCP, ETA) and UpToDate topic citations cited in the policy may be used to support medical necessity and documentation: UpToDate topics on diagnosis and laboratory assessment of thyroid disease, and others listed in the reference section.

UpToDate: Laboratory assessment of thyroid function; Diagnosis of hypothyroidism and hyperthyroidism
Guidelines: ACOG 2020; ATA/AACE 2017; Endocrine Society 2022; NICE NG145; ETA guidance

Note

Provider action — not specified in this section

Operational note — unspecified items: Some provider actions or payer prior authorization rules are not explicitly stated in this section. Check the payer's medical policy portal or contact prior authorization services for requirements related to specialty tests (eg, TRAb timing in pregnancy, repeat antibody testing intervals, or post‑transplant monitoring) before ordering.

Verify payer prior authorization for non‑routine or high‑cost assays
When policy is silent, include detailed clinical documentation to support testing

Key Definitions and Test Descriptions

TSH — Thyroid-stimulating hormone

DefinitionThyroid-stimulating hormone (TSH): a pituitary-derived hormone that regulates thyroid gland secretion of T4 and T3 and is the preferred initial test for assessing thyroid function (assuming steady-state conditions and absence of pituitary/hypothalamic disease).

Source contextTSH is secreted by the anterior pituitary and stimulates the thyroid to secrete T4 and T3; TSH measurement is the best initial assessment of thyroid function in most patients.

Clinical noteInterpretation depends on feedback from thyroid hormones; abnormal TSH warrants follow-up with free T4 (and free T3 when indicated).

Free thyroxine (fT4/FT4)

DefinitionFree thyroxine (fT4/FT4): the unbound fraction of thyroxine (T4) in serum; used to confirm thyroid status when TSH is abnormal and in evaluation of suspected central hypothyroidism or pregnancy-related discordance.

Pregnancy considerationDuring pregnancy, method-specific and trimester-specific reference ranges for fT4 are required; when reliable fT4 reference ranges are unavailable, total T4 may be preferable.

Clinical roleMeasure fT4 to determine degree of hypothyroidism when TSH is elevated and to clarify low TSH when assessing thyrotoxicosis.

Free triiodothyronine (fT3/FT3)

DefinitionFree triiodothyronine (fT3/FT3): the unbound fraction of triiodothyronine (T3); useful to evaluate hyperthyroidism when TSH is low and to help distinguish overt from subclinical thyrotoxicosis.

Assay limitationsCurrent immunoassays for T3 may disagree with reference methods (LC/MS/MS), and measurement accuracy can vary by method.

Clinical roleMeasure fT3 (or total T3) when TSH is suppressed to assess for thyrotoxicosis; avoid routine fT3 testing to monitor levothyroxine dosing in hypothyroid patients.

Chemiluminometric TSH assay — current generation assays

Assay typeChemiluminometric TSH assay: current-generation automated assays used to measure serum TSH.

Analytical sensitivityDetection limits approximately 0.01 mU/L, substantially more sensitive than older assays (~0.1 mU/L).

PerformanceProvide superior sensitivity to prior-generation assays and support distinguishing euthyroidism from hyperthyroidism in clinical use.

Reverse T3 — limited reliability

DefinitionReverse T3 (rT3): an inactive T3 isomer measured in some assays but of limited diagnostic reliability to distinguish hypothyroidism from euthyroidism.

EvidenceStudies report that reverse T3 may appear normal in hypothyroidism and low in euthyroidism; rT3 cannot reliably differentiate these states.

Policy implicationMeasurement of reverse T3 is of limited clinical value and is listed among tests that generally do not meet coverage except in specific contexts.

Biotin interference — assay interference and repeat testing guidance

Interference mechanismBiotin (high-dose) can interfere with biotin–streptavidin–based immunoassays, causing spurious thyroid test results.

Observed effectIngestion of 10 mg/day of biotin for one week was associated with clinically important assay interference in preliminary studies.

Testing guidanceIf biotin interference is suspected, repeat testing after stopping biotin (at least two days after cessation may be considered) to avoid inaccurate results.

Trimester-specific TSH reference ranges

Recommended rangesTrimester-specific TSH reference ranges recommended by ATA: first trimester 0.1–2.5 mIU/L; second trimester 0.2–3.0 mIU/L; third trimester 0.3–3.0 mIU/L.

Clinical practiceApply population- and method-specific trimester reference ranges when available; TSH is reduced in the first trimester due to hCG effects.

Laboratory noteNot all commercial labs provide trimester-specific fT4 reference ranges; when unavailable, total T4 with pregnancy-adjusted ranges may be used.

TRAb — use and recommended testing windows in pregnancy

Clinical useThyrotropin receptor antibodies (TRAb/TSH‑R‑Ab) are used to evaluate and monitor Graves disease in pregnancy and to assess fetal risk when maternal history suggests prior Graves disease or ablation.

Recommended timingFor women with prior Graves disease or prior ablation, obtain maternal TRAb early in pregnancy and repeat at 18–22 weeks; if elevated or if ATD therapy continues, repeat again in late pregnancy (30–34 weeks) per ATA/ETA guidance.

Fetal monitoring thresholdETA advises that if maternal TSH‑R‑Ab remains high (>3× the normal cutoff), monitor the fetus for thyroid dysfunction throughout pregnancy.

Subfertile — definition

DefinitionSubfertile: failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse.

Screening implicationETA recommends routine screening for thyroid disorders in women of subfertile couples due to associations between severe thyroid dysfunction and subfertility.

Clinical relevanceIdentify and treat overt thyroid dysfunction in subfertile patients as treatment can improve pregnancy outcomes; consider antibody testing where indicated by guidelines.

Central hypothyroidism (CeH) diagnostic confirmation

Diagnostic criteriaCentral hypothyroidism (CeH) confirmation: serum FT4 below the lower limit of normal with inappropriately low or normal TSH on at least two separate determinations, after exclusion of listed confounding conditions.

Supporting evaluationIsolated low FT3 or total T3 is not diagnostic of CeH and may reflect nonthyroidal illness or deiodination defects; monitor FT4/TSH periodically in patients with hypothalamic–pituitary disease.

Follow-up frequencyIn patients under follow-up for hypothalamic–pituitary disease, monitor FT4 and TSH at least biannually during childhood and yearly thereafter; consider CeH when FT4 falls into lower quartile or decreases >20% from prior values with low/normal TSH.

Laboratory assessment — referenced sources

Primary sourcesLaboratory assessment recommendations reference UpToDate and multiple guideline documents (e.g., ATA, Endocrine Society, NICE, ETA) and peer-reviewed studies.

Assay considerationsGuidance emphasizes assay method limitations (e.g., T3 immunoassays vs LC/MS/MS), reverse T3 unreliability, and biotin interference when interpreting results.

Clinical implicationUse TSH as first-line test and follow with fT4 (and fT3 when indicated); document clinical context to support testing per guideline-based algorithms.

Pregnancy thyroid guidelines — cited societies

Guidelines citedAmerican Thyroid Association (ATA) and Society for Maternal-Fetal Medicine (SMFM) guidance are cited for diagnosis and management of thyroid disease in pregnancy and postpartum.

Specific recommendationsATA: trimester-specific TSH ranges; SMFM/ACOG: no universal pregnancy screening and monitoring recommendations for high-risk individuals; ETA: serial monitoring after IRT and TRAb thresholds for fetal monitoring.

Use in policyThese guideline documents inform coverage indications, pregnancy monitoring frequency, TRAb testing windows, and assay interpretation considerations in the policy.

OpenPayer

Thyroid Disease Testing — Coverage Criteria

Coverage Criteria and Clinical Indications

Provider Actions, Documentation, and Operational Notes

Procedure Codes and Billing References

Background and Scope

Key Definitions and Test Descriptions

Revision History and References

80438	Thyrotropin releasing hormone (TRH) stimulation panel; 1 hour
80439	Thyrotropin releasing hormone (TRH) stimulation panel; 2 hour
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
84432	Thyroglobulin
84436	Thyroxine; total
84439	Thyroxine; free
84442	Thyroxine binding globulin (TBG)
84443	Thyroid stimulating hormone (TSH)
84445	Thyroid stimulating immune globulins (TSI)
84479	Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR)